急性非淋巴细胞性白血病(ANLL)常规化疗已有很大进展。不少病人可因此取得完全缓解,有的可取得治愈。其常规化疗的应用,在某些情况下,特别在支持治疗不充分的条件下,不无顾虑,如血细胞数过低,骨髓增生不良,合并严重感染或出血倾向,年老体弱或伴有其它严重疾病时等。10年前,对这部分病人开展了小剂量阿糖胞苷(LD—Arac)的应用,有 Acute non-lymphocytic leukemia (ANLL) conventional chemotherapy has made great progress. Therefore, many patients can achieve complete remission, and some can be cured. Its conventional chemotherapy, in some cases, especially in the case of inadequate supportive treatment, without any concerns, such as low blood cell count, poor myeloproliferation, with severe infection or bleeding tendency, frail or associated with Other serious diseases and so on. A decade ago, low-dose cytarabine (LD-Arac) was used in this group of patients, with